Rechercher des projets européens

27 projets européens trouvés

Recherche sur 125080 projets européens

 TERMINÉ 

SIMVASTATIN AND RIFAXIMIN AS NEW THERAPY FOR PATIENTS WITH DECOMPENSATED CIRRHOSIS (LIVERHOPE)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

Liver cirrhosis is a very common chronic disease and one of the leading causes of death in European. Moreover, cirrhosis has a marked impact in patients quality of life and represents a major burden for health systems. Treatment of cirrhosis is currently based on symptomatic management of complications and has not changed substantially in the last 20 years. There is an unmet need for therapies tha ...
Voir le projet

 18

 TERMINÉ 

Penumbral Rescue by Normobaric O=O Administration in Patients With Ischaemic Stroke and Target Mismatch ProFile: A Phase II Proof-of-Concept Trial (PROOF)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

Ischemic stroke (IS), caused by occlusion of arteries that supply blood to the brain, remains a leading cause of mortality and morbidity in the world. Disruption of blood and oxygen supply to the brain leads to neuronal death in the ischemic core within minutes. The hypoperfused tissue surrounding the ischemic core, the penumbra, is at high risk for infarction over time but still salvageable. Neur ...
Voir le projet

 13

 TERMINÉ 

Nanomedicine upscaling for early clinical phases of multimodal cancer therapy (NoCanTher)

Date du début: 1 avr. 2016, Date de fin: 31 mars 2021,

During the last four years the Multifun Consortium (FP7 project Nº. 262943) has developed and validated distinct nanoformulations as therapeutic approach against pancreatic and breast cancer. These nanoformulations are based on magnetic iron oxide nanoparticles (MNP) multifuntionalised with a target peptide and an anticancer chemical drug, allowing for a synergistic therapeutic effect produced by ...
Voir le projet

 13

 TERMINÉ 

Comorbid Conditions of Attention deficit / hyperactivity disorder (CoCA)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2020,

Understanding mechanisms underlying comorbid disorders poses a challenge for developing precision medicine tools. Psychiatric disorders are highly comorbid, and are among the last areas of medicine, where classification is driven by phenomenology rather than pathophysiology. We will study comorbidity between the most frequent psychiatric conditions, ADHD, mood/anxiety, and substance use disorders, ...
Voir le projet

 17

 TERMINÉ 

REgenerative Stem cell therapy for STroke in Europe (RESSTORE)

Date du début: 1 sept. 2015, Date de fin: 31 août 2020,

Stroke is the second leading cause of death in the world population. When not fatal, stroke often results in disability, due to motor and cognitive impairments, and secondary health problems affecting not only patients but also their families. Building on emerging preclinical and pilot clinical evidences, RESSTORE will focus on the clinical assessment of regenerative cell therapy to improve stroke ...
Voir le projet

 29

 TERMINÉ 

Brain injury and trauma monitoring using advanced photonics (BitMap)

Date du début: 1 janv. 2016, Date de fin: 31 déc. 2019,

Our vision is to develop a suite of standardised non-invasive devices that will provide essential information about brain health in neurocritical care and neuromonitoring, with a particular emphasis on 1. traumatic brain injury: the “silent epidemic of the third millennium” and 2. hypoxia in newborn children. Survivors present permanent neurological conditions that have a profound impact on the qu ...
Voir le projet

 11

 TERMINÉ 

Clinical evaluation of carbons of controlled porosity as a new therapeutic for the treatment of liver cirrhosis and non-alcoholic fatty liver disease. (CARBALIVE)

Date du début: 1 mai 2015, Date de fin: 31 oct. 2019,

Chronic liver disease affects about 29-million Europeans accounting for about 170,000 deaths at a cost of around €15.8bn. This chronic non-communicable disease is increasing at an alarming rate due to increasing European obesity, alcohol use and ageing. The three main causes of the disease; alcohol, fatty liver and viral hepatitis are amenable to prevention and treatment. Gut-derived endotoxins an ...
Voir le projet

 15

 TERMINÉ 

Mastering skills in the training Network for attention deficit hyperactivity and autism spectrum Disorders (MiND)

Date du début: 1 janv. 2015, Date de fin: 31 déc. 2018,

Attention deficit/hyperactivity disorder (ADHD) and autism spectrum disorders (ASD) are frequent, chronic and highly heritable neurodevelopmental disorders. Despite their societal importance, progress in understanding disease biology has been slow and no curative treatment options are available.The pan-European training network MiND aims to educate a new generation of researchers in the field of n ...
Voir le projet

 12

 TERMINÉ 

Aggression subtyping for improved insight and treatment innovation in psychiatric disorders (AGGRESSOTYPE)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2018,

Aggression is a basic physiological trait with important roles throughout evolution, both in defence and predation. When expressed in humans in the wrong context, aggression leads to maladjustment, social impairment and crime. Despite this, knowledge about aggression aetiology is limited and current treatment strategies are insufficient. Contingent to a subdivision into impulsive and instrumental ...
Voir le projet

 27

 TERMINÉ 

INCOMING FELLOWSHIPS BIOMEDICINE INSTITUT DE RECERCA VALL D’HEBRON (INCOMED)

Date du début: 1 sept. 2012, Date de fin: 28 févr. 2018,

"The INCOMED programme promotes 10 postdoctoral fellowships in all areas of biomedicine and clinical medicine at the Research Institute Vall d‘Hebron (IR-HUVH). This is an incoming mobility programme taht promotes training and career development that complies with the concept of individual trans-national mobility. It is addressed to experienced researchers capable of developing a competitive rese ...
Voir le projet

 1

 TERMINÉ 

European Training in Neural Regulation of Intestinal Function (NeuroGut)

Date du début: 1 févr. 2014, Date de fin: 31 janv. 2018,

"Neurogastroenterology is a new and emerging medical/scientific subspecialty that currently has no formal training opportunities in medicine and related disciplines. It includes basic science aspects (neurophysiology, neurobiology, neuropsychology, psychophysiology) and clinical aspects (gastroenterology, neurology, internal medicine, surgery, psychology, psychosomatic medicine) of the neural cont ...
Voir le projet

 12

 TERMINÉ 

Early Prevention of Diabetes Complications in people with Hyperglycaemia in Europe (E-PREDICE)

Date du début: 1 janv. 2012, Date de fin: 31 déc. 2017,

"Background: A significant proportion of pre-diabetics, show macro and micro vascular complications associated with hyperglycaemia. Although many trials have demonstrated the efficacy of lifestyle and pharmaceutical interventions in diabetes prevention, no trial has evaluated the extent to which mid- and long-term complications can be prevented by early interventions on hyperglycaemia.Aims: To ass ...
Voir le projet

 37

 TERMINÉ 

Framework to respond to regulatory needs of future nanomaterials and markets (FutureNanoNeeds)

Date du début: 1 janv. 2014, Date de fin: 31 déc. 2017,

Rapidly developing markets such as green construction, energy harvesting and storage, advanced materials for aerospace, electronics, medical implants and environmental remediation are potential key application targets for nanomaterials. There, nanotechnology has the potential to make qualitative improvements or indeed even to enable the technology. Impacts range from increased efficiency of energy ...
Voir le projet

 26

 TERMINÉ 

New epigenetic therapy for high-risk neuroblastoma (MIRNATHERAPYNBL)

Date du début: 1 oct. 2013, Date de fin: 30 sept. 2017,

Neuroblastoma (NBL) is the most common solid tumor of infancy. Nearly 45% of all children with NBL are designated as high-risk patients and 60% of them die. Therefore, there is an urgent need to identify and target the molecular programs that are responsible for NBL aggressiveness, especially those that contribute to metastasis and resistance to chemotherapy.Recently, it has become evident that mi ...
Voir le projet

 1

 TERMINÉ 

Assessment and mitigation of nano-enabled product risks on human and environmental health: Development of new strategies and creation of a digital guidance tool for nanotech industries (GUIDENANO)

Date du début: 1 nov. 2013, Date de fin: 30 avr. 2017,

The main objective of GUIDEnano is to develop innovative methodologies to evaluate and manage human and environmental health risks of nano-enabled products, considering the whole product life cycle. A strategy to identify hot spots for release of nanomaterials (NMs) will be followed by decision trees to guide on the use of (computational) exposure models and, when necessary, design of cost-effecti ...
Voir le projet

 34

 TERMINÉ 

Anti-Biopharmaceutical Immunization:Prediction and analysis of clinical relevance to minimize the risk (ABIRISK)

Date du début: 1 mars 2012, Date de fin: 28 févr. 2017,

The ABIRISK project provides an integrated approach to the study of immunization against biopharmaceuticals, bringing together a unique panel of experts from different disciplines. ABIRISK will involve many of the European leaders in rheumatology, gastroenterology, hemophilia and multiple sclerosis, caring for ~30,000 patients treated with biopharmaceuticals, with ~10,000 additional patients recru ...
Voir le projet

 39

 TERMINÉ 

European multicentre, randomised, phase III clinical trial of hypothermia plus best medical treatment versus best medical treatment alone for acute ischaemic stroke (EuroHYP-1)

Date du début: 1 févr. 2012, Date de fin: 31 janv. 2017,

The consortium led by UKER and EuroHYP, the European Stroke Research Network for Hypothermia, proposes a large, multicentre clinical trial which will assess mild hypothermia as a novel treatment for ischemic stroke.Stroke is the second cause of death world-wide and the second cause of lost disability-adjusted life years in high-income countries. Stroke incidence rises exponentially with age, so it ...
Voir le projet

 38

 TERMINÉ 

Best EScalation Treatment in Multiple Sclerosis (MS) (BEST MS)

Date du début: 1 nov. 2012, Date de fin: 31 oct. 2016,

"Multiple Sclerosis (MS) is a devastating disease of the central nervous system affecting 2.5 million worldwide. MS is a field of constant therapeutic innovation, a fact which brings hope to young adults since MS is one of the most frequent causes of severe handicap. A major unmet need is to rationalize treatment decisions. To date, there is no way of predicting which patients will best respond to ...
Voir le projet

 5

 TERMINÉ 

PREventive Care Infrastructure based On Ubiquitous Sensing (PRECIOUS)

Date du début: 1 nov. 2013, Date de fin: 31 oct. 2016,

PRECIOUS: PREventive Care Infrastructure based On Ubiquitous Sensing will provide a preventive care system to promote healthy lifestyles, which is comprised of three components: (1) transparent sensors for monitoring user context and health indicators (food intake, sleep and activity) deliver ambient data about current user behavior; (2) users are represented by individual virtual models which all ...
Voir le projet

 8

 TERMINÉ 

European Consortium for the Early Treatment of Diabetic Retinopathy (EUROCONDOR)

Date du début: 1 mars 2012, Date de fin: 30 juin 2016,

Diabetic retinopathy (DR), the leading cause of blindness among working-age individuals in developed countries has been classically considered to be a microcirculatory disease of the retina. However, there is growing evidence to suggest that retinal neurodegeneration is an early event in the pathogenesis of DR. For this reason, it is reasonable to hypothesize that therapeutic strategies based on n ...
Voir le projet

 18

 TERMINÉ 

Unraveling metabolic settings and targeting metabolic enzymes with selective lethality in BRAF and NRAS mutant melanoma tumors (METABOSET)

Date du début: 1 avr. 2014, Date de fin: 31 mars 2016,

Melanoma is the most lethal form of skin cancer. Therapeutic alternatives to metastatic melanoma are very limited. Activation of RAS pathway appears to be the central motor driving melanoma development and maintenance, where BRAFV600E and NRASQ61L are found in ~ 50% and 20% of human melanomas, respectively. Although, these mutually exclusive mutations affect the same pathway emerging preclinical a ...
Voir le projet

 1

 TERMINÉ 

Multicentre Preclinical Animal Research Team (Multi-PART)

Date du début: 1 sept. 2013, Date de fin: 31 août 2015,

Millions of Europeans still suffer the consequences of neurological disease, but the number of new drugs coming to market continues to fall. Reasons for the failure of stroke drug efficacy to translate from animals to clinical trials is probably best studied, but the problem is widespread. The economic and social costs of translational failure are substantial; a new approach to translational medic ...
Voir le projet

 12

 TERMINÉ 

PROTEOMIC IDENTIFICATION OF BIOMARKERS IN BIOFLUIDS AND IN PRECLINICAL MODELS FOR THE EARLY DIAGNOSIS AND PROGNOSIS OF CANCER (PROT*BIO*FLUID) (PROTBIOFLUID)

Date du début: 1 août 2011, Date de fin: 31 juil. 2015,

1.6 million people are killed worldwide each year due to ovarian, endometrial, bladder and prostate cancers. The key to making treatment breakthrough is early diagnosis.PROTBIOFLUID is a new network for developing innovative early diagnostic techniques and for spreading this knowledge through the medical community by a systematic exchange of staff to create high impact benefits to patients and tra ...
Voir le projet

 2

 TERMINÉ 

Molecular Mechanisms of Glioma Genesis and Progression (Glioma)

Date du début: 1 août 2008, Date de fin: 31 juil. 2014,

Glioma is the most common and aggressive tumour of the brain and its most malignant form, glioblastoma multiforme, is nowadays virtually not curable. Very little is known about glioma genesis and progression at the molecular level and not much progress has been achieved in the treatment of this disease during the last years. The understanding of the molecular mechanisms involved in the biology of ...
Voir le projet

 3

 TERMINÉ 

United Europeans for the Development of Pharmacogenomics in Multiple Sclerosis (UEPHA-MS)

Date du début: 15 sept. 2008, Date de fin: 14 sept. 2012,

"Multiple sclerosis (MS) is a chronic inflammatory, disabling disease of the central nervous system. Recent studies suggest that over the last 50 years a disproportional increase in incidence of MS in women has taken place. The lifetime costs of MS exceed 1.5 million € per case in the UK, and are likely to be similar in other European countries. There is no definitive cure for MS. Immunomodulatory ...
Voir le projet

 12

 TERMINÉ 

Modelling cancer in Caenorhabditis elegans (canceromics)

Date du début: 1 oct. 2007, Date de fin: 31 mars 2012,

Cancer is a complex disease that results from accumulation of diverse alterations in the genome. There are more than 300 genes identified as “cancer genes” although it is estimated that there are many more involved in cancer development that could be significant during tumorigenesis and putative targets for drugs therapies. Several scientific groups are performing a comprehensive sequencing of gen ...
Voir le projet

 2

 TERMINÉ 

The European Advanced Translational Research Infrastructure in Medicine (EATRIS)

Date du début: 1 janv. 2008, Date de fin: 31 déc. 2010,

Efficient translation of research discoveries into industrial application is an essential element to maintain Europe’s competitiveness in the biomedical and health industry. The main bottleneck is the lack and the fragmented nature of essential research infrastructure and know-how, leading to unacceptable delays and/or preventing the development of new innovative medicines. The aim of EATRIS is to ...
Voir le projet

 20